Evidence map›Paper›PMID 40504271›Full record

ReviewCell biology and toxicology2025

Oral squamous cell carcinoma: Insights into cellular heterogeneity, drug resistance, and evolutionary trajectories.

Yang Zhou, Liyin Wang, Minghua Liu, Hongfang Jiang, Yan Wu

Abstract readReview
In one paragraph

Review in Cell biology and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Modulation ofInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yang Zhou *Department of Obstetrics and Gynaecology, Shengjing Hospital of China Medical University, No.36, Sanhao Street, Shenyang, 110000, China.
Liyin Wang *Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, 110000, China.
Minghua Liu *Departmentof Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, 110000, China.
Hongfang JiangDepartment of Geriatrics, Shengjing Hospital of China Medical University, Shenyang, 110000, China. jianghf@sj-hospital.org.
Yan WuDepartment of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China. 13066673069@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC) can lead to metastasis and high mortality rates known for its aggressive and invasive properties. Currently, primary treatment options of surgical resection, chemotherapy and radiotherapy have many therapeutic limitations for OSCC patients due to its dynamic evolutionary pathways and the development of resistance to conventional therapies. Moreover, previous studies fail to emphasize the roles of cellular heterogeneity, drug resistance, and evolutionary trajectories in OSCC. This review explores the intricate tumor microenvironment landscape of OSCC, focusing on the cellular heterogeneity, drug resistance, and evolutionary trajectories as well as genetic, epigenetic, and environmental risk factors contributing to the OSCC progression. Tumor heterogeneity arises from environmental exposures (e.g., tobacco, HPV infection, dietary carcinogens) that drive clonal evolution, creating subpopulations of cells with distinct mutational profiles and therapeutic vulnerabilities. Recent advances in in the precision medicine and combination therapy of OSCC paves the way for innovative therapeutic strategies, such as targeting molecular subclones through real-time monitoring and leveraging computational models to predict treatment response. By recognizing tumor heterogeneity as both a driver of therapeutic resistance and a therapeutic target, precision medicine frameworks can integrate environmental risk factor data, molecular profiling, and early detection tools to optimize outcomes. This review underscores the necessity for a multidisciplinary approach to understand and combat the complexity of OSCC, proposing directions for future research to enhance diagnosis and treatment efficacy.

Indexed as

Carcinoma, Squamous CellDrug Resistance, NeoplasmMouth NeoplasmsHumansRisk FactorsTumor MicroenvironmentCellular heterogeneityDrug resistanceEvolutionary trajectoriesOral squamous cell carcinoma (OSCC)

Identifiers

PMID40504271
PMCPMC12162747

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.